Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) - Total Liabilities
Based on the latest financial reports, Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) has total liabilities worth CN¥4.79 Billion CNY (≈ $700.86 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hunan Dajiaweikang Pharmaceutical Indust liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 301126 total asset value.
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Holley Inc
NYSE:HLLY
|
USA | $712.63 Million |
|
Liaoning Shidai Wanheng Co Ltd
SHG:600241
|
China | CN¥187.60 Million |
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
USA | $1.74 Billion |
|
Best Pacific International Holdings Limited
F:NWQ
|
Germany | €2.77 Billion |
|
Oneconnect Financial Technology Co
NYSE:OCFT
|
USA | $1.32 Billion |
|
Turvo International Co Ltd
TW:2233
|
Taiwan | NT$3.11 Billion |
|
Hai An Transport and Stevedoring JSC
VN:HAH
|
Vietnam | ₫3.32 Trillion |
|
Panama Petrochem Limited
NSE:PANAMAPET
|
India | Rs4.50 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Hunan Dajiaweikang Pharmaceutical Indust to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.75 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (2019–2025)
The table below shows the annual total liabilities of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.74 Billion ≈ $694.20 Million |
+9.57% |
| 2024-12-31 | CN¥4.33 Billion ≈ $633.54 Million |
+23.84% |
| 2023-12-31 | CN¥3.50 Billion ≈ $511.58 Million |
+65.36% |
| 2022-12-31 | CN¥2.11 Billion ≈ $309.37 Million |
+60.76% |
| 2021-12-31 | CN¥1.32 Billion ≈ $192.45 Million |
+13.33% |
| 2020-12-31 | CN¥1.16 Billion ≈ $169.82 Million |
+11.82% |
| 2019-12-31 | CN¥1.04 Billion ≈ $151.86 Million |
-- |
About Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd engages in the wholesale and retail of pharmaceuticals products in China. It provides raw materials, biological products, chemical drugs, Chinese herbal medicines, medical devices, and other products. The company also offers Chinese patent medicines in the form of granules, capsules, particles, tablets, slices, and pills; foods, such as beverages… Read more